�����г���Ƶ

Journal Article

1. Curtin K, Stein JD, Stagg BC, Fino N, Conley M, Johnson T, Patil A, Paulson C, Pompoco C, Wirostko BM (2024). Identifiable historic and observable factors may predict progression to exfoliation glaucoma in newly-diagnosed exfoliation patients. Ophthalmol Glaucoma. ()
2. Riina N, Harris A, Siesky BA, Ritzer L, Pasquale LR, Tsai JC, Keller J, Wirostko B, Arciero J, Fry B, Eckert G, Verticchio Vercellin A, Antman G, Sidoti PA, Guidoboni G (2024). Using Multi-Layer Perceptron Driven Diagnosis to Compare Biomarkers for Primary Open Angle Glaucoma. Invest Ophthalmol Vis Sci, 65(11), 16. ()
3. Polski A, Long T, Stagg BC, Wirostko B (2024). Uveitis-Glaucoma-Hyphema Syndrome from Subtle Malposition of a Hydrus Microstent. J Glaucoma. ()
4. Polski A, Liu KC, Gupta D, Grewal DS, Horns J, Wirostko BM, Stagg BC (2023). Incident glaucoma and ocular hypertension after periocular and intravitreal steroid injections: a claims-based analysis. BMJ Open Ophthalmol, 8(1). ()
5. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2023). The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports. Ophthalmol Ther. ()
6. Patil A, Conley M, Pompoco C, Paulson C, Taylor S, Swiston C, Herrick JS, Ritch R, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome in Utah. Acta Ophthalmol, 101(4), 449-456. ()
7. Roy Chowdhury U, Pervan-Steel CL, Sheeler R, Sookdeo HK, Rogers B, Casale R, Dosa PI, Htoo T, Wirostko BM, Fautsch MP (2023). Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent. J Ocul Pharmacol Ther, 39(5), 332-346. ()
8. Patil A, Conley M, Paulson C, Pompoco C, Wallace R, Swiston RR, Curtin K, Wirostko B (2022). Abdominal aortic aneurysm and exfoliation syndrome: A literature review comparing single site findings . Acta Ophthalmol (Copenh), 101(5), 478-484.
9. Paulson C, Barker DJ, Pompoco C, Taylor S, Conley M, Patil A, Amakiri N, Stagg B, Ritch R, Kang JH, Wiggs JL, Curtin K, Wirostko B (2022). Association of Non-Melanoma Skin Carcinomas and UV Exposure with Exfoliation Syndrome in Utah. Med Res Arch, 10(10).
10. Guidoboni G, Nunez R, Keller J, Wikle C, Robinson EL, Verticchio A, Siesky B, Oddone F, Quaranta L, Wirostko B, Topouzis F, Cheng C-Y, Januleviciene I, Wegner A, Antman G, Jones C, Harris A (2022). Precision medicine and glaucoma management: how mathematical modeling and artificail intelligence help in clinical practice. Online Journal. Expert Rev Ophthalmol, 17(5).
11. Patil A, Swiston C, Wallace RT, Paulson C, Conley ME, McCoy L, Chaya C, Wirostko B (2022). Exfoliation Syndrome and Exfoliation Glaucoma in the Navajo Nation. An ARVO publication. ARVO Annual Meeting Abstract Search and Program Planner, 63(7), 1641.
12. Levin AM, McGlumphy EJ, Chaya CJ, Wirostko BM, Johnson TV (2022). The utility of home tonometry for peri-interventional decision-making in glaucoma surgery: Case series. Am J Ophthalmol Case Rep, 28, 101689. ()
13. Wirostko BM, Curtin K, Taylor SC, Paulson C, Pompoco C, Besch BM, Ranjan R, Ritch R (2022). Risk of atrial fibrillation is increased in patients with exfoliation syndrome: the Utah project on exfoliation syndrome (UPEXS) . Acta Ophthalmol, 100(4).
14. Huang JJ, Geduldig JE, Jacobs EB, Tai TT, Ahmad S, Chadha N, Buxton DF, Vinod K, Wirostko BM, Kang JH, Wiggs JL, Ritch R, Pasquale LR (2022). Head and Neck Region Dermatological Ultraviolet-Related Cancers are Associated with Exfoliation Syndrome in a Clinic-Based Population . Ophthalmol Glaucoma, 5(6), 663-671.
15. Pervan-Steel CL, Chowdhury UR, Sookdeo HK, Casale RA, Dosa PI, Htoo TM, Fautsch MP, Wirostko BM (2022). Ocular Hypotensive Properties and Biochemical Profile of QLS-101, a Novel ATP-Sensitive Potassium (KATP) Channel Opening Prodrug. Invest Ophthalmol Vis Sci, 63(4), 26.
16. Sharma A, Riaz KM, Gill MS, Patnaik A, Ulahannan SV, Wang JS, Gombos DS, Ang Q, Cicic D, Bergonio GR, Zhang C, Wirostko BM (2021). Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol, 57(2), 118-126. ()
17. Paulson C, Thomas SC, Gonzalez O, Taylor S, Swiston C, Herrick JS, McCoy L, Curtin K, Chaya CJ, Stagg BC, Wirostko BM (2022). Exfoliation Syndrome in Baja Verapaz Guatemala: A Cross-Sectional Study and Review of the Literature. J Clin Med, 11(7). ()
18. Pompoco CJ, Curtin K, Taylor S, Paulson C, Shumway C, Conley M, Barker DJ, Swiston C, Stagg B, Ritch R, Wirostko BM (2021). Summary of Utah Project on Exfoliation Syndrome (XPEXS): Using a large database to identify systemic comorbidities . BMJ Open Ophthalmol, 6(1), e000803.
19. Levin AM, Chaya CJ, Kahook MY, Wirostko BM (2021). Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short and Long-term Considerations. J Glaucoma, 30(12), 1019-1026.
20. Levin AM, Vezina D, Wirostko BM (2021). Home-Based Intraocular Pressure Measurements: Tracing a Parallel with Out-of-Office Blood Pressure Measurement. Ophthalmol Glaucoma, 4(3), 235-237.
21. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9. ()
22. Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummings M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9.
23. Kang JH, VoPham T, Laden F, Rosner BA, Wirostko B, Ritch R, Wiggs JL, Qureshi A, Nan H, Pasquale LR (2021). Cohort Study of Nonmelanoma Skin Cancer and the Risk of Exfoliation Glaucoma. J Glaucoma, 29(6), 448-455. ()
24. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. ( J Ocul Pharmacol Ther 2019;35(7):381-387) . J Ocul Pharmacol Ther, 36(4), 205.
25. Perez VL, Wirostko B, Korenfeld M, From S, Raizman M (2019). Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications. J Ocul Pharmacol Ther, 36(2), 75-87. ()
26. Taylor SC, Bernhisel AA, Curtin K, Allingham RR, Ritch R, Wirostko BM (2018). Association between Chronic Obstructive Pulmonary Disease and Exfoliation Syndrome: The Utah Project on Exfoliation Syndrome. Ophthalmol Glaucoma, 2(1), 3-10. ()
27. Besch BM, Curtin K, Ritch R, Allingham RR, Wirostko BM (2018). Association of Exfoliation Syndrome With Risk of Indirect Inguinal Hernia: The Utah Project on Exfoliation Syndrome. JAMA Ophthalmol, 136(12), 1368-1374. ()
28. Wirostko B, Allingham R, Wong J, Curtin K (2018). Utah Project on Exfoliation Syndrome (UPEXS): Insight Into Systemic Diseases Associated With Exfoliation Syndrome. J Glaucoma, 27 Suppl 1, S75-S77. ()
29. Durrie DS, Wolsey D, Thompson V, Assang C, Mann B, Wirostko B (2018). Ability of a new crosslinked polymer ocular bandage gel to accelerate reepithelialization after photorefractive keratectomy. J Cataract Refract Surg, 44(3), 369-375. ()

Review

1. Asrani SG, McGlumphy EJ, Al-Aswad LA, Chaya CJ, Lin S, Musch DC, Pitha I, Robin AL, Wirostko B, Johnson TV (2024). The relationship between intraocular pressure and glaucoma: An evolving concept. [Review]. Prog Retin Eye Res, 103, 101303. ()

Editorial

1. Johnson C, Pasquale LR, Wirostko B (2024). Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma? Ophthalmol Glaucoma, 7(5), 419-421. ()
2. Johnson C, Pasquale LR, Wirostko B (2024). Glucagon-Like Peptide 1 Receptor Agonists: A Role in Glaucoma? Ophthalmol Glaucoma, 7(5), 419-421. ()
3. Mai AP, Wirostko B, Fitch S, Hansen K, Imbrescia W, Stagg BC (2023). Using Technology to Address Ophthalmic Technician Shortages in Glaucoma Clinics. Ophthalmol Glaucoma, 6(6), 567-569. ()
4. Mai AP, Wirostko B, Fitch S, Hansen K, Imbrescia W, Stagg BC (2023). Using Technology to Address Ophthalmic Technician Shortages in Glaucoma Clinics. Ophthalmol Glaucoma, 6(6), 567-569. ()

Letter

1. Delsoz M, Raja H, Madadi Y, Tang AA, Wirostko BM, Kahook MY, Yousefi S (2024). A Response to: Letter to the Editor Regarding "The Use of ChatGPT to Assist in Diagnosing Glaucoma Based on Clinical Case Reports.". [Letter to the editor]. Ophthalmol Ther. ()
2. Wirostko B, Mann B, Stirland D (2020). Re: "Cross-Linked Hyaluronic Acid as Tear Film Substitute" by Posarelli et al. (J Ocul Pharmacol Ther 2019;35(7):381-387). [Letter to the editor]. J Ocul Pharmacol Ther, 36(4), 205. ()

Abstract

1. Amakiri N, Branham K, Jayasundera TK, Andrews, Chris A, Milentijevic D, Narayanan D, Johnson T, Jensen J, Wirostko BM, Stein JD (2023). Leveraging the Sight Outcomes Research Collaborative (SOURCE) Repository to Identify Patients with RPGR-Related Retinitis Pigmentosa  [Abstract]. 64(8), 4664.
2. Chang M, Harris A, Zaid M, Sala L, Szopos M, Lapin S, Kuvin J, Ciulla TA, Pasquale LR, Wirostko BM, Verticchio V, Alice C, Antman G, Siesky BA, Guidoboni G (2023). The Impact of reduced left ventricular contractility on retinal perfusion, ARVO 2023 [Abstract]. 64(8), 1997.
3. Kellner, R, Harris A, Rosen RB, Wirostko BM, Siesky BA, Verticchio V, Alice C, Coleman-Beli JC, Tessone I, Chang M, Fabczak-Kubicka A, Antman G (2023). Non-glaucomatous persons with diabetes have reduced macular capillary density potentially elevating the risk for glaucoma [Abstract]. 64(8), 4721.
4. Kazemi A, Wirostko B, Fautsch M, Htoo T, Sit AJ (2023). Diurnal Variations in Episcleral Venous Pressure  [Abstract]. 64(8), 3473.
5. Johnson T, Wirostko B, Stein J, Stagg B, Amakiri N, Jensen J (2023). Understanding the Disease Course of RPGR-Linked vs. RP2-Linked Retinitis Pigmentosa, ARVO 2023 [Abstract]. 64(8), 4667.

Other

1. (2023). Glaucoma Under Pressure, The Ophthalmologist July/August 2023. The Ophthalmologist.

Patent

1. Wiroskto, Barbara for Jade Therapeutics, LLC (2013). Ocular Drug Delivery System - including a composition in which a formulation having an active agent (e.g. HDH,rHGH or an HDH mimic) that increases insulin growth factor (IGF) or that alters insulin grouwth factor binding protein (IGFBP) in a subject is dispersed in a pharmaceutical carrier. The composition is configured for placement in, around or on an eye of the subject, and the composition provides controlled release of an amount of the active agent to the eye effective to promote ocular surface and corneal neural regeneration and wound healing. U.S. Patent No. WO/2013/158661 (PCT/US2013/036807). Washington, D.C.:U.S. Patent and Trademark Office.
2. Wirostko, Barbara for Jade Therapeutics (2013). Application #4-HGH for Ocular Diseases. U.S. Patent No. 61/956,070. Washington, D.C.:U.S. Patent and Trademark Office.
3. Wirostko, Barbara for Jade Therapeutics, LLC (2012). Application #2 - Dermal Wound Healing. U.S. Patent No. 61/58, 1845. Washington, D.C.:U.S. Patent and Trademark Office.
4. Wirostko, Barbara for Jake Therapeutics (2012). Application #3 -Corneal Re-Innervation. U.S. Patent No. 3246-005. Washington, D.C.:U.S. Patent and Trademark Office.
5. Wirostko, Barbara for Jade Therapeutics, LLC (2011). Application #1- Corneal Wound Healing. U.S. Patent No. 61/62,4730. Washington, D.C.:U.S. Patent and Trademark Office.

News

• Utah Population Database Helps Glaucoma Researcher Learn More About Disease